Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP)-mediated Pathway

Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome

(2012) Sherman M Chamberlain et al.   Expert Opinion On Drug Safety

Use of the Chloride Channel Activator Lubiprostone for Constipation in Adults with Cystic Fibrosis: A Case Series

(2010) Catherine E O'Brien et al.   ANNALS OF PHARMACOTHERAPY

Lubiprostone targets prostanoid EP4 receptors in ovine airways

(2010) AW Cuthbert   BRITISH JOURNAL OF PHARMACOLOGY

Lubiprostone Reverses the Inhibitory Action of Morphine on Mucosal Secretion in Human Small Intestine

(2010) Xiaohong Sun et al.   DIGESTIVE DISEASES AND SCIENCES

Activation of Intestinal Cl− Secretion by Lubiprostone Requires the Cystic Fibrosis Transmembrane Conductance Regulator

(2009) Marcel J.C. Bijvelds et al.   GASTROENTEROLOGY

Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon

(2008) A K Bassil et al.   BRITISH JOURNAL OF PHARMACOLOGY

Inhibition of cyclooxygenase-2 and EP1 receptor antagonism reduces human colonic longitudinal muscle contractility in vitro

(2008) Scott D. Smid et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS